The US-based firm, which provides the pharma industry with services in engineering, design, building, validation and compliance of facilities, said that with the new Indian offices IPS can meet the demand of pharma companies offshoring to India. Indeed, the move comes at a time when India's drug manufacturing industry is tipped to grow 10 per cent over the next three years as more pharma firms shift some or all of their manufacturing operations there to cut costs. In addition, India has lifted its game in the drug making arena of late, striving to provide standards of international quality, and now has the largest number of US Food and Drug Administration (FDA) approved plants on a worldwide scale, according to recent industry data. Many of these facilities are expected to contract and manufacture on-patent pharmaceutical and biologic drugs and active pharmaceutical ingredients (APIs) over the next few years, the company said. As a result, pharma companies need support to design and build their facilities in order to stay compliant in a global regulatory environment, IPS said. "New offices in Hyderabad and New Delhi formalise our presence in this growing drug development region to meet client demand for engineering and technical expertise," stated David Goswami, president of IPS. "By focusing on technically complex and high performance areas, we believe that our combination of global capabilities and in-depth knowledge delivers compliance-driven projects that improve operational performance and accelerate time-to-market for clients worldwide." IPS said it will focus on oral solid dosage (OSD), biopharmaceuticals and injectable containment facilities using potent and cytotoxic compounds, in addition to the range of services the firm already provides.
The firm already has five offices in the US and one in Puerto Rico.